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Abstract
Objective To provide a framework for addressing payers’
criteria during the development of pharmaceuticals.
Methods A conceptual framework was presented to an
international health economic expert panel for discussion.
A structured literature search (from 2010 to May 2015),
using the following databases in Ovid: Medline and
Medline In-Process (PubMed), Embase (Ovid), EconLit
(EBSCOhost) and the National Health Service Economic
Evaluation Database (NHS EED), and a ‘grey literature’
search, were conducted to identify existing criteria from
the payer perspective. The criteria assessed by existing
frameworks and guidelines were collated; the most
commonly reported criteria were considered for inclusion
in the framework. A mnemonic was conceived as a
memory aide to summarise these criteria.
Results Overall, 41 publications were identified as poten-
tially relevant to the objective. Following further screening,
26 were excluded upon full-text review on the basis of no
framework presented (n = 13), redundancy (n = 11) or
abstract only (n = 2). Frameworks that captured criteria
developed for or utilised by the pharmaceutical industry
(n = 5) and reimbursement guidance (n = 10) were
reviewed. The most commonly identified criteria—unmet
need/patient burden, safety, efficacy, quality-of-life out-
comes, environment, evidence quality, budget impact and
comparator—were incorporated into the summary frame-
work. For ease of communication, the following mnemonic
was developed: BEACON (Burden/target population,
Environment, Affordability/value, Comparator, Outcomes,
Number of studies/quality of evidence).
Conclusions The BEACON framework aims to capture the
‘essence’ of payer requirements by addressing the most
commonly described criteria requested by payers regarding
the introduction of a new pharmaceutical.
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Key Points for Decision Makers
There are a variety of existing frameworks and
guidelines that can be used by payers (budget
holders) to assess new pharmaceutical therapies.
However, these tools are not designed to inform
internal decision making within a pharmaceutical
company, involving multiple stakeholders
throughout drug development.
This review of existing frameworks and guidelines
identified common criteria for decision making
relating to new pharmaceuticals from the payer
perspective: burden/unmet need, safety, efficacy and
quality-of-life outcomes, environment, evidence
quality, budget impact and comparator.
We developed a new framework—BEACON—
which could be used to guide the development of a
new pharmaceutical from the payer perspective, to
effectively communicate payer needs to different
functions or stakeholders within pharmaceutical
companies and to inform global decision making
within a pharmaceutical company.
1 Background
The traditional pharmaceutical development model focus-
ses on building the evidence to meet registration require-
ments for regulatory approval (e.g. the US Food and Drug
Administration [FDA] or European Medicines Agency
[EMA]) [1, 2]. However, pharmaceutical companies are
increasingly aware that regulatory approval is not the final
hurdle and that payers’ (i.e. organisations that fund
healthcare for patients, such as insurers or national health
systems) needs must also be addressed [1–3]. Clinical
societies such as the American Society of Clinical Oncol-
ogy have also recognised the need to communicate more
widely on therapy value (beyond solely clinical benefit) to
aid treatment decision making, recently publishing a con-
ceptual framework to assess the value of cancer treatment
options [4].
Payers need to carefully consider the optimal allocation
of limited healthcare resources to their patient population;
these decisions are complex and must take practical and
budgetary considerations into account [5]. In many coun-
tries, these multifaceted decisions are enabled through a
comprehensive health technology assessment (HTA),
which consolidates the medical, economic, social and
ethical implications of a new healthcare intervention [4–9].
Although recent efforts from international bodies such as
the European Network for Health Technology Assessment
(EUnetHTA) aim to standardise data requirements across
Europe, complete transferability or standardisation of
decision making is not possible, because of intrinsic dif-
ferences between countries in terms of public healthcare
expenditure, healthcare system structures or treatment
pathways [2, 7]. Additionally, it is acknowledged that
payer requirements not only vary between countries, but
can also vary within countries, at regional and local levels
[2, 3].
Demonstration of value to payers globally is therefore
a significant challenge, which is further complicated by
the need to address the requirements of the multiple
internal stakeholders involved in pharmaceutical devel-
opment. For instance, during the initial stages of clinical
development (e.g. phase I or II), the main focus is on the
safety and efficacy of a healthcare product. However,
payer requirements should also be taken into considera-
tion even at this early stage, e.g. defining a specific
target population with an unmet need and identifying the
appropriate clinical outcomes. During the later stages of
development (phase III onwards), the same principles
apply from the payers’ perspectives; however, other
requirements such as improved quality of life (QoL) and
added clinical benefits over current therapies are also
taken into consideration to determine how a healthcare
product will provide incremental value in comparison
with existing treatments. Given the time-consuming nat-
ure of clinical development and the resource use asso-
ciated with it, it is imperative that the right decisions are
made in order to pursue healthcare products that meet
payers’ needs. However, within pharmaceutical compa-
nies, there is a broad array of functions integral to
pharmaceutical development (medical, commercial,
patent, manufacturing, drug safety, regulatory, etc.) that
may have conflicting interests, which are not necessarily
aligned with payer needs. It is widely acknowledged that
barriers in communication can exist across these func-
tions [10], which may impede the incorporation of the
payer perspective throughout development.
This has been acknowledged by other bodies (e.g. HTA
bodies); thus, initiatives such as the Shaping European
Early Dialogues (SEED) project are currently ongoing in
order to inform pharmaceutical companies of specific payer
needs through early discussions. The project (sponsored by
the European Commission) is a consortium of 14 HTA
bodies from ten countries, led by Haute Autorite´ de Sante´
(HAS). The objective of this project is to improve collab-
oration and exchange of information between HTA bodies
and pharmaceutical companies during initial phases of
clinical development (e.g. phase I or II) in order to
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overcome any potential limitations of national reimburse-
ment or to inform on specific requirements of HTA bodies
for different types of data [11, 12]. While initiatives such as
the SEED project are necessary, they also emphasise the
importance of internal alignment of stakeholders within
pharmaceutical companies in order to effectively cooperate
to meet payers’ needs.
Aligning pharmaceutical development with the
requirements of payers will increase the probability of
success and ensure timely access for patients [2, 3].
Integrating the needs of the payer into pharmaceutical
development requires consideration and understanding of
the payer perspective across the entire organisation.
However, within global pharmaceutical companies, there
can be considerable confusion regarding the varying
requirements of reimbursement agencies and payers
across jurisdictions [2, 13]. Similarly, although frame-
works have been developed that propose criteria to be
used in the assessment and evaluation of new pharma-
ceuticals, the proposed criteria vary widely across these
frameworks. We therefore sought to develop a summary
framework that captures the ‘essence’ of international
payer requirements, which could be used to guide the
development of a new pharmaceutical from the payer
perspective, to effectively communicate payer needs and
to inform global decision making within a pharmaceuti-
cal company. To the best of our knowledge, no previous
publication has aimed to summarise the criteria that
capture payer requirements from an international
perspective.
2 Methods
The primary objective of this research was to inform the
development of a new framework through identification of
existing criteria of tools, guidelines and frameworks
(henceforth collectively referred to as frameworks) from
the published literature. Although many frameworks con-
sist of four core components—identification of criteria,
measurement, valuation and aggregation—this manuscript
explores only the identification of criteria from existing
frameworks. The criteria assessed by existing frameworks
were collated, and the most commonly reported criteria
that were deemed to be of significance from the payer
perspective were considered for inclusion in the summary
framework. To aid in the recall and utilisation of the
framework by pharmaceutical companies, a mnemonic was
developed that captured the criteria summarised by the
framework.
The overall development of the summary framework to
date is outlined in Fig. 1.
2.1 Pilot Conceptual Framework
The first stage of the research involved developing a pilot
framework. A pilot conceptual framework, termed
‘PICOP’ (Population, Intervention, Comparator, Outcomes
and Price), was developed on the basis of the existing PICO
(Population, Intervention, Comparator, Outcomes) frame-
work commonly used in academia to guide the formulation
of research questions [14]. This initial framework was
developed on the basis of internal discussions within the
market access team at Mundipharma International Limited.
It was created to capture the main discussion points within
the team following multiple reviews of therapies either
from a business development perspective (i.e. licensing
deals or partnerships with other pharmaceutical companies)
or the clinical study design context. The pilot framework
aimed to capture the key criteria considered by payers, and
it can be summarised as follows:
• Population: is the population well defined, and does it
have a clear unmet need?
• Intervention budget impact: what will payers perceive
as the budget impact?
• Comparator: will clinical data be available versus the
relevant comparator/standard of care?
• Outcome: are the clinical endpoints and outcomes
appropriate and meaningful?
• Price: is the price justifiable on the basis of these and
other factors?
The pilot framework was presented and applied at an
international advisory board meeting (in Vienna, December
2014). The members of the advisory board were all leaders
Fig. 1 Development of the summary framework
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in their respective fields, with the vast majority having
more than 20 years of related experience. The advisory
board focused on considerations in the development of new
therapies, but clinical and regulatory experts were also
invited to provide specialised input. The advisory board
included a mix of health economic experts (n = 14),
clinicians (n = 3) and regulatory personnel (n = 1) from
Brazil, Canada, France, Germany, Italy, Mexico, the
Netherlands, Spain, Sweden, the UK and the USA, all of
whom were invited to participate as key opinion leaders in
their respective fields. Of those in attendance, a panel of
health economic and clinical experts, including three of the
authors of this publication (CDM, OP and RG) [Canada:
n = 1; France: n = 2; Germany: n = 1; Spain: n = 1; UK:
n = 2; USA: n = 3] provided formal feedback via a post-
meeting questionnaire (see ‘‘Appendix 1’’). The overall
response to the framework was positive, with the majority
of participants indicating that the framework captured all
(n = 2) or most (n = 8) of the key dimensions that would
be considered by a payer during evaluation of a new
pharmaceutical.
The pilot framework was also presented to and utilised
by different functional teams within an international
pharmaceutical company (Mundipharma International
Limited; see the Acknowledgments section). The tool was
used to engage with a number of different functions,
including business development, regulatory, medical sci-
ence, marketing and medical affairs. These findings indi-
cated that the pilot conceptual framework may be
applicable to the assessment of pharmaceuticals from the
payer perspective and was a worthwhile endeavour; how-
ever, further validation of the criteria to be included was
required.
2.2 Literature Review
To ensure that the tool captured the criteria that were of
importance to payers globally, a review of the published
literature was conducted to identify existing frameworks.
The structured search was conducted electronically using
the following databases in Ovid (Ovid Technologies, Inc.):
Medline and Medline In-Process (PubMed), Embase
(Ovid), EconLit (EBSCOhost) and the National Health
Service Economic Evaluation Database (NHS EED). The
search was limited to the English language only. The
search was limited to a 5-year time horizon (from 2010 to
May 2015) to identify the most up-to-date literature; it was
assumed that more recent publications would refer back to
existing tools (published prior to 2010). The search string is
presented in ‘‘Appendix 2’’. Additionally, the reference list
of each publication was reviewed to identify any additional
publications of interest, and grey literature was identified
from a broad internet search using the following key terms:
‘framework’, ‘drug development’ and ‘decision making’.
Overall, 230 abstracts were screened from the structured
literature review (Fig. 2); of these, 41 publications were
identified as publications potentially of interest and were
taken forward to full-text review. Publications of interest
were required to fulfil the following inclusion criterion:
publications reporting on frameworks that were developed
to assess the value of a new pharmaceutical from a
healthcare system, payer or pharmaceutical company per-
spective. A further 26 publications were excluded at full-
text review. The majority of publications excluded at full-
text review were conceptual papers (n = 13), which com-
mented on the need for a framework to assess the value of a
new pharmaceutical but presented no frameworks. An
additional 11 publications were considered to be redundant
at full-text review and were subsequently excluded,
i.e. numerous publications presented risk–benefit assess-
ments in early clinical development.
A review of HTA guidance was also conducted to
understand the key criteria that national payers currently
use to assess new pharmaceuticals. The review was limited
Fig. 2 Selection of publications from the structured literature review.
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to guidance from countries with well-established and
publically available HTA guidelines, in order to provide an
indication of the different perspectives taken in interna-
tionally influential HTA countries. This included guidance
published by EUnetHTA [15], Canadian Agency for Drugs
and Technologies in Health (CADTH) [16], HAS [17],
Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesund-
heitswesen (IQWiG) [8], Pharmaceutical Benefits Advisory
Committee (PBAC) [9], National Institute for Health and
Care Excellence (NICE) [6], Belgian Health Care Knowl-
edge Centre (KCE) [18, 19] and Tandva˚rds- och la¨keme-
dels-fo¨rma˚nsverket (TLV) [20].
3 Results
3.1 Evaluation of Existing Tools and Frameworks
In total, five frameworks and ten HTA guidelines were
reviewed. Although this list was not exhaustive, the
frameworks considered in this paper represent a sample of
those utilised by the pharmaceutical industry to align to
payer requirements. Additionally, a number of decision-
making approaches were identified, such as risk–benefit
analyses and multicriteria decision analysis (MCDA); these
approaches were captured, where possible, through the
evaluation of representative tools, e.g. the Clinical Utility
Index and the Evidence and Value: Impact on Decision
Making (EVIDEM) framework, respectively [21, 22]. The
following frameworks were included within this review:
• Clinical Utility Index: a quantitative risk–benefit
assessment of the value of a new medical intervention.
• Evaluation of Pharmaceutical Innovations with Regard
to Therapeutic Advantage (EVITA): a tool for early
evaluation of the additional therapeutic value of a drug.
• International Society for Pharmacoeconomics and
Outcomes Research/Academy of Managed Care Phar-
macy/National Pharmaceutical Council (ISPOR-
AMCP-NPC) Good Practice Task Force questionnaire:
to assess the relevance and credibility of observational
studies.
• EVIDEM framework: to assess healthcare interven-
tions, using an MCDA core model and context-specific
decision criteria.
• Institute for Clinical and Economic Review value
framework: an approach to assessing the value of a new
healthcare intervention in the USA.
• Cancer Drugs Fund (CDF) assessment: a budget allo-
cation prioritisation tool.
• Ontario Decision Determinants (DD) framework: a
complementary framework to guide HTA in Ontario,
Canada.
• HTA guidance published by EUnetHTA, CADTH,
HAS, IQWiG, PBAC, KCE, TLV and NICE.
These existing frameworks and guidance were reviewed
and categorised on the basis of (1) their purpose or appli-
cation; and (2) their perspective. Each framework was
evaluated to identify any criteria that were of relevance
from the payer perspective, to be incorporated into the new
conceptual framework.
3.2 Categorisation of Frameworks
The frameworks were broadly classified as non-HTA or
HTA frameworks:
1. Non-HTA decision-making frameworks: evidence-
based, academic or healthcare system perspective to
assess the quality of evidence.
2. HTA guidance: healthcare system payer perspective,
assessing the clinical, economic, social and ethical
implications of a new pharmaceutical to aid HTA
decision making.
However, it was acknowledged the majority of the
frameworks feed into the HTA process, and a degree of
overlap exists.
3.3 Non-HTA Decision-Making Frameworks
A summary of the criteria considered in the ‘non-HTA
decision-making’ frameworks is provided in Table 1. As
can be seen in the table, there is a wide variety of different
approaches taken. Some frameworks utilise a more clinical
approach (such as the Clinical Utility Index), whereas
others take an approach that is closer to the payer
perspective.
Risk–benefit frameworks, such as the approach taken by
the Clinical Utility Index, are commonly used by phar-
maceutical companies and regulatory agencies in drug
development and pre-approval. The Clinical Utility Index
combines multiple attributes of a product profile with
appropriate weighting to generate a single utility value, and
it has previously been implemented in early exploratory
development programmes or at the ‘proof of concept’
stage, i.e. to assess whether the available evidence suggests
that success is ‘reasonably likely’ on the basis of the
presence of key success attributes and lack of failure
attributes [21, 27]. However, these risk–benefit tools, such
as the Clinical Utility Index, may inform the likelihood of
clinical efficacy or safety but do not necessarily link to the
commercial viability of the intervention: estimates suggest
that in 2005/2006, approximately 50 % of pharmaceuticals
that achieved proof of concept proceeded to development.
Of these, the registration rate varied from approximately
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20 % for cardiovascular drugs to 8–12 % for oncology
drugs, despite oncology drugs having the highest rate of
successful ‘proof of concept’ [27].
It has also been acknowledged that appropriate com-
parative clinical evidence, demonstrating an additional
therapeutic value of a pharmaceutical, may be lacking at
the time of the launch because of the use of inadequate
comparators, control groups or outcomes. The EVITA tool
was developed as a simple, transparent tool for early
evaluation of the additional therapeutic value of a phar-
maceutical. The tool assesses clinical benefit, e.g. im-
proved efficacy and reduced adverse events, and follows an
algorithm that captures the relevance of outcomes and the
strength of evidence [23].
Furthermore, the volumes of data required to demon-
strate the incremental benefit of a new pharmaceutical are
increasing. A number of tools have been developed to aid
in the critical appraisal of evidence, such as an assessment
tool for prospective observational studies developed by an
ISPOR task force [24]. This tool consists of 33 questions to
assess the relevance and credibility of a study, and it was
developed to allow an individual to critically appraise an
individual study to assess whether it is of sufficient quality
to be included within a body of evidence for a new tech-
nology appraisal.
Two further approaches—MCDA and a US-based payer
assessment framework—were identified, which were con-
sidered to be more closely aligned with the purpose of the
pilot conceptual framework (i.e. to take into account bud-
getary factors that can influence decision makers in an
ever-increasingly resource-constrained environment),
rather than focusing on clinical data. Moreover, MCDA
takes into consideration multiple criteria and scores each
criterion on the basis of importance or relevance to gen-
erate an overall estimate [28]. An MCDA-based decision-
making approach has already been piloted by the Office of
Health Economics (OHE) for the assessment of orphan
indications in the UK [29], and in the USA, there is an
MCDA-based decision-making framework for prioritisa-
tion of vaccines [28]. However, it is important to note that
this type of approach to assessments is not widely used by
major HTA bodies such as HAS, IQWIG or NICE. The
EVIDEM framework has been developed to assess
healthcare interventions using an MCDA core model and
context-specific decision criteria with the aim of bridging
HTA and MCDA approaches [22]. EVIDEM assigns 15
decision-making determinants to form an MCDA value
matrix (Table 1). Each criterion is scored, and a weight is
allocated to generate a final score. However, there are some
components that are not quantifiable, such as ethical factors
(opportunity costs, population priority, access and fairness)
and context (system capacity and appropriate use of an
intervention). Furthermore, some methodological issues
have also been identified that can arise when applying this
method to HTA—in particular, choosing the criteria to
include in the decision process, choosing an appropriate
Table 1 Summary of criteria included within the non-HTA decision-making frameworks
Framework name Key criteria assessed
EVITA [23] Quality of RCTs (appropriateness of comparator, patient-relevant outcomes and acceptable surrogate outcomes),
therapeutic benefit and risk profile (clinically relevant therapeutic benefit versus comparator and acceptable risk
profile versus comparator) and clinical relevance of outcomes (number needed to treat and number of RCTs
conducted)
ISPOR task force [24] Relevance (of population, interventions, outcomes and context) and credibility (study design, data, analysis,
reporting, interpretation and conflicts of interest)
Clinical Utility Index
[21, 25]
This is not a defined framework per se; each attribute is defined and weighted on the basis of the decision-making
context. The majority of examples combine two attributes: safety and efficacy to define the optimal dose early in
clinical development
EVIDEM [22] Quantitative appraisal: unmet need (disease severity, size of affected population and comparator limitations),
comparative outcomes (improvement in efficacy/effectiveness and patient-perceived health), type of benefit
(preventive and/or therapeutic benefit), economic consequences (budget impact, costs and impact on medical or
non-medical costs) and knowledge of intervention (quality of evidence and expert consensus/guidelines)
Qualitative appraisal: mandate and scope of healthcare system, population priorities and access, common goal and
specific interest, environmental impact, opportunity costs/affordability, system capacity and appropriate use of
intervention, context
Institute for Clinical and
Economic Review [26]
Clinical care value (comparative clinical effectiveness, additional benefits, contextual considerations and incremental
cost per outcomes achieved) and health system value (managing affordability and budget impact)
EVIDEM Evidence and Value: Impact on Decision Making, EVITA Evaluation of Pharmaceutical Innovations with Regard to Therapeutic
Advantage, ISPOR International Society for Pharmacoeconomics and Outcomes Research, RCT randomised controlled trial
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scoring or weighting method, or modelling scores and
weights [30, 31]. Although interest in the MCDA approach
has been expressed, there is a lack of guidance on the
appropriate approach to conducting such an analysis, and
the complexity and length of the analysis may impact upon
its wider utilisation.
A US-based payer assessment framework is also being
developed by the Institute for Clinical and Economic
Review [26]. This value framework is a categorical, part
quantitative, part qualitative approach to assessing the
value of a pharmaceutical. The tool aims to improve the
reliability and consistency of decisions by payers and to
provide the basis for transparent discussions between the
pharmaceutical company and decision makers when value
is being considered [26].
3.4 HTA Guidance
Established HTA agencies (e.g. CADTH, HAS, IQWiG,
PBAC, KCE, TLV and NICE) inform decisions on cover-
age and reimbursement for a new pharmaceutical. Both
comparative effectiveness and cost effectiveness are
considered within these assessment procedures, which are
detailed in Table 2.
Some frameworks place a greater emphasis on certain
criteria—for example, NICE in the UK, PBAC in Aus-
tralia, KCE in Belgium and TLV in Sweden focus on the
economic element of the review in cost–utility or cost-
effectiveness analyses presented by pharmaceutical com-
panies, alongside assessments of the comparative clinical
benefit [6, 9, 18–20, 28]. All of the frameworks consider
life-years gained or quality-adjusted life-years (QALYs) as
appropriate measures of effect in economic analyses;
however, it is worth pointing out that only NICE uses a
specific threshold for each QALY gained (i.e. £20,000–
£30,000) [6], and TLV uses an individual’s willingness to
pay per QALY gained threshold rather than a set budgetary
threshold, while PBAC and KCE do not use an explicit
cost-effectiveness threshold when assessing new pharma-
ceuticals [9, 18, 32]. Despite that, it is important to note
that within single countries, there may be different payer
bodies, depending on the geography or the nature of the
pharmaceutical. For example, the NICE assessment pro-
cedure is not applied to all new pharmaceuticals launched
in the UK and, in addition, the CDF was established in




CADTH [16] Target population, comparators, cost and cost-effectiveness measures, clinical efficacy, clinical safety, outcome measures,
equity
CDF [34]a Magnitude of survival benefit, QoL, toxicity in comparison with the existing active standard therapy, clinical unmet need, cost
per quality-adjusted life-year, cost and strength of evidence
DD [37] Overall clinical benefit, consistency with expected societal and ethical values, value for money and feasibility of
implementation in the current healthcare system
EUnetHTA
[15]
Comparators, budget impact, costs, clinical outcome measures, cost effectiveness, net monetary health and net monetary benefit
HAS [17, 38] Additional clinical benefit, health outcomes relative to the comparator, cost effectiveness, cost–utility, impact on the healthcare
system
IQWiG [8] Patient-relevant medical benefit, patient-relevant harm and weighting of the benefit and harm, including relative additional
benefit over the appropriate comparator
PBAC [9] Target population, market share, comparators, clinical efficacy, clinical safety, QoL, cost and cost effectiveness, patient-
relevant outcomes, medicine quality, risk sharing, equity
NICE [6] Background information on the disease, technology, population, comparators, evidence base, health outcome measures, cost
and cost-effectiveness measures, equity
KCE [18, 19] Target population, comparator, clinical effectiveness, cost effectiveness or cost–utility, patient groups, implications for QoL,
economic implications for the patient, ethical issues, equity, impact on the healthcare system, budget impact on healthcare
system
TLV [20] Target population, comparator, cost effectiveness, clinical effectiveness
CADTH Canadian Agency for Drugs and Technologies in Health, CDF Cancer Drugs Fund, DD Decision Determinants, EUnetHTA European
Network for Health Technology Assessment, HAS Haute Autorite´ de Sante´, IQWiG Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesund-
heitswesen, KCE Belgian Health Care Knowledge Centre, NICE National Institute for Health and Care Excellence, PBAC Pharmaceutical
Benefits Advisory Committee, QoL quality of life, TLV Tandva˚rds- och la¨kemedels-fo¨rma˚nsverket
a Information correct at the time of writing
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2010 to provide access to cancer therapies that are not
approved or not reviewed by NICE [33]. The assessment
criteria used by the CDF, in its current form, are slightly
different from those used by NICE, mainly prioritising the
magnitude of survival and toxicity, as well as unmet need
and strength of evidence over costs and cost effectiveness
(Table 2) [33, 34]. However, it is worth noting that a new
assessment process led by NICE for the appraisal of cancer
drugs is expected in 2016 [35].
In other established HTA countries in Europe, there is a
different approach by payers to the assessment of new
technologies. In Germany, there is a clear separation of the
assessment of added clinical benefit from the assessment of
cost effectiveness [8]. In particular, IQWiG is usually
commissioned by the Gemeinsamer Bundesausschuss (G-
BA) to conduct an early benefit assessment of a health
technology to determine whether there is proof of added or
comparable patient-relevant clinical benefit. Price negoti-
ations are completed only following a decision on the
added patient-relevant clinical benefit of a pharmaceutical.
In exceptional cases, i.e. when pricing negotiations fail to
reach an agreement between a pharmaceutical company
and the national statutory health insurance association, a
health economic analysis may be conducted [8]. On the
other hand, in France, clinical assessments are carried out
first during the HTA of a new pharmaceutical, followed by
economic evaluations if an appropriate level of clinical
benefit is achieved and if the new pharmaceutical is
anticipated to have a significant budget impact on the
healthcare system. However, their outputs are used to
inform different decisions. For example, the added clinical
benefit of a medical intervention is used as a criterion for
reimbursement decisions, while cost-effectiveness results
are used during pricing negotiations [36].
Because of the recognised differences in approaches
across Europe, the European body EUnetHTA has also
developed a core framework for the assessment of phar-
maceuticals, which embodies all of the core criteria typi-
cally used across Europe (Table 2).
Furthermore, in addition to national HTA processes,
extra guidance has been developed to complement the
national HTA process. For example, in Canada, in addition
to a national body review by the CADTH [16], there are
regional drug assessments, such as those conducted by the
Ontario Health Technology Advisory Committee
(OHTAC). OHTAC has developed its own framework for
assessment (the Ontario DD framework), which also
encompasses many of the national-level assessment criteria
but explicitly includes an assessment of the feasibility of
implementation in the current healthcare system, which is
important for regional or local-level decision making [37].
The identified frameworks assess a broad range of criteria,
each of which has differing subcriteria or associated key
questions, which vary depending on the perspective taken and
the purpose of the tool or framework. The criteria assessed by
each framework were categorised into 11 broader criteria:
efficacy outcomes, safety outcomes, QoL outcomes, unmet
need, environment, evidence quality, cost, comparator, ethics,
indication and pharmaceuticals. All of the frameworks con-
sider the clinical safety and efficacy outcomes (n = 15) as a
key criterion, whereas fewer consider the dosing or formula-
tion of a new pharmaceutical (n = 9) or ethics (n = 8); this is
summarised in Fig. 3, which provides an overview of the
criteria that are currently covered by the existing tools dis-
cussed in the preceding sections.
3.5 Development and Application of the BEACON
Framework
The frameworks outlined in Tables 1 and 2 were reviewed,
and all criteria that were relevant from the payer perspec-
tive were considered for inclusion within the new frame-
work (Fig. 3). The selection of the criteria deemed relevant
to payers was based on a consensus from all authors of the
manuscript.
As the overall objective was to develop a simple
communication tool, the overall number of discrete cri-
teria included were limited by grouping similar criteria
into broader single criterion. For instance, the most
frequently identified criteria were efficacy (n = 15),
safety (n = 15) and QoL (n = 13), all of which repre-
sent outcomes; therefore, these were combined as a
single criterion. Other criteria such as comparator
(n = 13), unmet need (n = 12), cost (n = 12) and evi-
dence quality (n = 11) were also frequently assessed by
the frameworks reviewed and thus were considered by
the authors to be important and distinct enough to war-
rant separate categories. Indication (n = 10), environ-
ment (n = 10), pharmaceutics (n = 9) and ethics
(n = 8) were the least frequently identified criteria.
Indication, pharmaceutics and ethics were not regarded
as unique drivers of decision making from the payer
perspective. Consequently, these three criteria were
grouped with other categories defined above. Key
aspects for ‘indication’, which are required for regula-
tory licensing, were incorporated under the headings of
common categories that were also likely to be of interest
to the payer: ‘unmet need’ and ‘outcomes’. Pharmaceu-
tics, which included dosing formulation and pharma-
cokinetics, were considered potential influencers on the
appropriateness of comparators and outcomes, and thus
were included under the ‘comparator’ and ‘outcomes’
categories. Ethical considerations were taken into
account under the ‘environment’ heading. Environ-
ment—which takes into account aspects such as clinical
guidelines, drug reimbursement and healthcare
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systems—which are of importance to payers in their
decision making, was also included as a single criterion.
Therefore, overall, six broad categories to be included in
the final communication framework were identified from
the existing frameworks in descending order of frequency:
outcomes, comparator, unmet need (or burden/target pop-
ulation), affordability/value and cost (to encompass the
broad range of considerations relating to costs, cost
effectiveness and budgetary implications, which are of
importance to the payer), number of studies/evidence
quality, and environment.
The proposed list of key criteria for inclusion in the
framework and the key questions and sub-questions to be
answered are detailed in Table 3.
For ease of communication of this framework, we pro-
pose the following mnemonic, based on the identified
broad categories: BEACON (Burden/target population,
Environment, Affordability/value, Comparator, Outcomes,
Number of studies/quality of evidence). The BEACON
mnemonic was perceived to be simple to remember and
reflective of the purpose of the summary framework, as the
term has connotations of ‘guiding’ stakeholders through
complex payer requirements.
It is recognised that the proposed BEACON framework
provides a broad set of criteria and that in practice, the sub-
questions are likely to be adapted to the respective situa-
tion, e.g. the stage of the pharmaceutical life cycle, the
country and local payer priorities.
As a payer’s perception of the value of a pharma-
ceutical may be influenced by a number of factors, we
propose that all criteria are assessed within the context of
an overarching value statement and target product pro-
file, i.e. to differentiate between decisions on expensive
pharmaceuticals that are associated with a significant
clinical benefit and decisions on pharmaceuticals whose
clinical efficacy and safety are equivalent to those of the
standard of care but that are associated with a cost
saving.
Figure 4 demonstrates how the BEACON framework
could be applied when payer-focused decisions are being
made regarding a biosimilar, orphan drug product or high-
cost oncology product (all of which are hypothetical
products). A colour-coding system is proposed to highlight
key areas where focus is required in the development of the
new pharmaceutical, in a simple manner. It is recognised
that there will be differences between regions—therefore,
this assessment would need to be undertaken from different
perspectives—and also that, depending on the decision
problem, greater complexity may be required than the
example applications presented in Fig. 4.
On the basis of this description of the benefits of the new
pharmaceuticals, pharmaceutical companies can then
effectively communicate the potential value of a new in-
development pharmaceutical to a range of stakeholders
(both internally and externally) in order to shape the future
development of the pharmaceutical.
*The authors acknowledge a number of criteria could overlap across the summary criteria reported in Figure 3 e.g. 
idenﬁcaon of populaon and unmet need or indicaon. To avoid ‘double counng’ each criteria within a framework was 
captured under a single criteria within the summary 
Fig. 3 Summary of the criteria
covered by the identified
frameworks
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4 Discussion
A variety of tools and guidelines are used by payers to
assess new pharmaceutical therapies. Each of these is
important within a certain context, whether this is to per-
form early evaluations of a pharmaceutical’s additional
therapeutic benefits (e.g. EVITA) or to inform decisions on
reimbursement (i.e. HTA guidance). However, these tools
are not designed for the purposes of internal decision
making involving multiple stakeholders throughout all
stages of pharmaceutical drug development.
From the frameworks identified in this manuscript,
several key themes and common criteria were identified.
These included unmet need/patient burden, environment,
budget impact or cost considerations, safety, efficacy, QoL
outcomes, comparator and overall quality of evidence.
In contrast to the existing frameworks and tools, the
proposed BEACON framework and mnemonic allow the
identification of criteria to guide the development of a
pharmaceutical from a payer perspective, to aid with
communication and internal decision making within phar-
maceutical companies. For instance, value frameworks
developed by organisations such as the American College
of Cardiology and American Heart Association (ACC and
AHA), the American Society of Clinical Oncology
(ASCO) and the National Comprehensive Cancer Network
Table 3 Key criteria included in the BEACON mnemonic
Criteria Key questions to be answered Sub-questions to be answered
B Burden/target
population
Is the new pharmaceutical addressing a
population with a healthcare burden?
Is the patient population well defined and from a well-understood
target indication, therefore reducing the uncertainty for payers
when planning for changes to their budget?
Is the new pharmaceutical for a population with a high unmet need?
Is the population a payer priority?
E Environment Does the healthcare environment facilitate
patient access?
Are challenges to the implementation of the new medical therapy
likely?
Are there any incentives or disincentives among stakeholders for the
medicine to be used?
Are there any ethical considerations?
What is the expected payment system, e.g. risk share agreements or
co-payment?
For which setting is the new pharmaceutical to be used, e.g. clinical
or outpatient?
A Affordability/value Is the new pharmaceutical priced so it is
affordable and of value to healthcare systems?
Are cost savings expected versus the standard of care?
What is the total budget impact?
What is the pricing of similar therapies?
Is the pharmaceutical cost effective (as determined by cost–utility
analyses)?
What is the timeframe for realising the benefits to the healthcare
system?
C Comparator Are the data generated versus an appropriate
comparator, from a payer’s perspective?
Are the data generated versus the appropriate comparator, i.e. the
standard of care?
Are the data generated using the appropriate dosage, duration and
administration compared with the comparator?
O Outcomes Are the comparative outcomes (including
efficacy, safety and QoL) meaningful?
Have appropriate endpoints been incorporated?
Is the magnitude of clinical/patient-relevant benefit meaningful
versus the appropriate comparator?
Are the outcomes associated with resource saving?
N Number of studies/
quality of
evidence
Does the quality of evidence and number of
studies sufficiently support all of the above
assumptions?
Are the clinical studies appropriately robust, i.e. a phase III RCT in
a large patient population?
Is there any real-world evidence to support these clinical studies?
Are there any well-conducted meta-analyses or systematic reviews
available?
Are these findings generalisable?
Have a sufficient number of patients been included across the
studies?
QoL quality of life, RCT randomised controlled trial
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Therapy X is priced at 
10–30% below 
originator therapy and 
has equivalent clinical 
eﬃcacy and safety. 
Therapy X substanally 
improves quality of life 
in paents with no 
other therapy opons, 
and is priced at €50,000 
per course of therapy. 
Therapy X improves 
paent progression free 
survival by 3 months 
(which does not 
represent a signiﬁcant 
added clinical beneﬁt) 
and is priced at 50% 
more than the current 
standard of care. 
B Burden/Target populaon 
Populaon already 
deﬁned by clinical data 
from the reference 
product. 
Fulﬁls an economic 
unmet need and may 
be associated with 
greater paent access, 
but does not provide an 
added clinical beneﬁt to 
individual paents 
compared to the 
reference product. 
Populaon deﬁned by 
genec tesng and 
physician assessment. 
No licensed treatments 
currently available for 
the paent populaon. 
95% of paents 
incapacitated by 30 
years of age. Current 
standard of care only 
eﬀecve in 5% of 
aﬀected paents. 
Populaon deﬁned by 
biomarkers.  
The current standard of 
care is well tolerated as 
a third line therapy for 
the majority of paents. 
E Environment 
Naonal iniaves in 
place to increase 
prescribing of 
biosimilars (e.g. 
France), but some 
clinicians/paent 
groups may be 
reluctant. 
Polical pressure to 
support paent 
populaons with 
greatest unmet need. 
Disincenves to fund 
expensive cancer 
therapies with minimal 
incremental clinical 
beneﬁt as resources 
may need to be 
directed away from 
exisng high unmet 
need areas. 
A Aﬀordability / value 
Favourable impact on 
health budgets due to 
10–30% cost reducon 
per ﬁrst-line treatment 
course compared to the 
reference product. 
Minimal budget impact 
due to small paent 
populaon (3/100,000 
in Europe). However, 
high net price per 
treatment and 
therefore not cost-




thresholds (e.g. NICE 
threshold in UK).  
High net price per 
treatment incurred by 
healthcare system and 





thresholds (e.g. NICE 
threshold in UK). 
C Comparator 
Data generated versus 
original reference 
product. 
Single arm study due to 
ethical consideraons 
of ineﬃcacious 
Data generated versus 
the standard of care. 
standard of care 
comparator and lack of 
historical comparators. 
O Outcomes 
Eﬃcacy, safety and QoL 
outcomes are 
equivalent to those of 
the reference product. 
20% reducon in the 
proporon of paents 
incapacitated by 30 
years of age. Paents 
living on average 5 
years longer.  
Paent progression free 
survival extended by up 
to 3 months. 
Comparable safety and 
QoL outcomes to the 
standard of care. 
N 
Number of 
studies / quality 
of evidence 
Phase I and III RCTs 
conducted in a single 
indicaon and 
extrapolated to other 
licensed indicaons. 
Phase III RCTs 
conducted in a 
representave paent 
populaon for an 
orphan disease (n=70). 
Phase III RCTs 
conducted in a 
representave paent 
populaon (n=476). 
Study duraon of 6 
months.  
Key: 
 = likely to support market access 
 = risk of negave impact on market access  
 = likely negave impact on market access 
 = neutral (unlikely to impact market access) 
QoL: Quality of life; RCT: randomised controlled trial. 
NICE: Naonal instute for health and care excellence
Fig. 4 Case study of BEACON
use for assessing three
hypothetical new medicines
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(NCCN) all include clinical efficacy and safety criteria
assessments, as well as cost effectiveness and budget
impact, but they do not take into account disease burden,
market access opportunities or QoL outcomes. Moreover,
these approaches aim to include user preferences by
assigning weights or scores to the various dimensions they
assess, which in turn may produce inconsistent results [39].
On the other hand, the BEACON framework uses a colour-
coding system, which can be used to highlight areas where
potential market access challenges might arise and where
more focus is required in the pharmaceutical development.
The colour-coding system can also be used to communicate
these challenges to other functional teams within a phar-
maceutical company in a simplified manner and to ensure
that a payer-led perspective is integrated throughout all
stages of development at all team levels.
Given the many different criteria and the different
emphasis of payers globally, a framework such as BEA-
CON, which consolidates the different needs, will help
multinational companies (who need to consider a global
perspective) make informed decisions. In addition, com-
municating the value of a new pharmaceutical by using this
framework will aid the different functions and stakeholders
within pharmaceutical companies to understand the payer
perspective and incorporate that into decision making for
pharmaceutical development or in-licensing. Applying this
framework when assessing the value of a pharmaceutical
will also enable a consistent approach, to maximise the
chance of successful development and patient access. It is
anticipated that this framework could be used at multiple
stages of the pharmaceutical life cycle, to take into account
the changing external landscape and to ensure that the
development strategy is refined on the basis of the latest
payer needs. Additionally—although this was not explored
within this manuscript—it is assumed that the framework
may be broadly applicable to the assessment of other
healthcare interventions, e.g. medical devices.
To inform decision making in practice, it is likely that
the use of the BEACON framework will be based on
research such as discussions with payers, reviews of similar
drug case studies, development of health economic models
and real-world evidence.
It is recognised that the proposed BEACON framework
provides a broad set of criteria and that an adapted version of
BEACON that incorporates specific local payer require-
ments may be required when decisions are being made for
local application. Implementation of the framework should
never be a substitute for other review processes and the use of
more complex guidelines or tools. Given BEACON’s
potential to facilitate internal alignment within a pharma-
ceutical organisation, the tool could also be used to improve
early discussions between pharmaceutical companies and
payers. For instance, the SEED project has been recently
initiated with the aim of advising pharmaceutical companies
how to optimise their development strategies in order to meet
payers requirements. Some of the main topics covered by the
SEED project are also covered by BEACON; these include
the target population, comparators, clinical trial design
(e.g. duration, drug dosage), clinical endpoints, subgroup
analyses and economic analyses [11, 12]. This suggests that
the broad nature of the criteria incorporated into the BEA-
CON framework could potentially help pinpoint areas that
should be discussed within the context of a more complex
tool.
The framework presented here is based on a review of
the literature and distillation of the key payer requirements
into a core set of criteria. As the review of the published
literature was limited to a 5-year time horizon and a
focused review of established HTA guidance, it is
acknowledged that the core set of criteria presented within
this manuscript is not an exhaustive list of criteria that may
be of consideration for payers. Therefore, additional
research needs to be conducted to further validate the
proposed framework, to assess its sensitivity and general-
isability and how the framework performs in terms of
identifying products that have a high probability of market
access success. In addition, further consideration should be
given to how the criteria within the tool are scored and
whether weighting of the different categories is required in
order to effectively communicate value and inform deci-
sion making. Finally, there is a potential need to further
develop the framework to take into account internal com-
pany resources, long-term strategic goals, pipeline balance
and spread across therapy areas and stages of clinical
development, all of which can also influence internal
decision making on pharmaceutical development.
5 Conclusions
Both pharmaceutical companies and payers are under
increasing pressure to meet the growing healthcare needs
of society. To ensure that innovative pharmaceuticals are
reaching the market, and to ensure timely access for
patients, pharmaceutical companies need to focus on
intelligent innovation by instilling payer decision makers’
needs through the entire development process. The intro-
duction of a framework such as BEACON, as proposed
here, will provide a tool to guide pharmaceutical devel-
opment from the payer perspective.
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Appendix 1
Appendix 2
Structured literature review search string
1. (‘Decision making’ or ‘health economics’ or ‘health technology
assessment’ or ‘outcome assessment’ or ‘evidence based
medicine’ or ‘biomedical technology assessment’ or ‘payer
assessment’ or ‘early evaluation’ or ‘healthcare cost’ or ‘early
benefit assessment’ or ‘risk benefit analysis’ or ‘forecasting’ or
‘reimbursement’).mp. [mp = ti, ot, ab, sh, hw, kw, tn, dm, mf,
dv, nm, kf, px, rx, an, ui, tc, id, tm, ct, tx]
2. ‘Drug development’.mp. [mp = ti, ot, ab, sh, hw, kw, tn, dm,
mf, dv, nm, kf, px, rx, an, ui, tc, id, tm, ct, tx]
3. (‘Framework’ or ‘tool’ or ‘guidelines’).mp. [mp = ti, ot, ab, sh,
hw, kw, tn, dm, mf, dv, nm, kf, px, rx, an, ui, tc, id, tm, ct, tx]
4. 1 and 2 and 3
5. Limit 4 to English language
6. Limit 5 to yr = ‘2009–current’
7. Remove duplicates from 6
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